about
Environmental factors and their regulation of immunity in multiple sclerosisRegenerative Capacity of Macrophages for RemyelinationRemyelination therapy for multiple sclerosisThe role of EMMPRIN in T cell biology and immunological diseasesDetecting deoxyhemoglobin in spinal cord vasculature of the experimental autoimmune encephalomyelitis mouse model of multiple sclerosis using susceptibility MRI and hyperoxygenationEMMPRIN, an upstream regulator of MMPs, in CNS biologyCellular factors promoting resistance to effective treatment of glioma with oncolytic myxoma virus.Inefficient clearance of myelin debris by microglia impairs remyelinating processesUsing magnetic resonance imaging in animal models to guide drug development in multiple sclerosis.Understanding disease processes in multiple sclerosis through magnetic resonance imaging studies in animal models.Iron in multiple sclerosis: roles in neurodegeneration and repair.Targeting progressive neuroaxonal injury: lessons from multiple sclerosis.Cleavage of osteopontin by matrix metalloproteinase-12 modulates experimental autoimmune encephalomyelitis disease in C57BL/6 mice.Reduction of PrP(C) in human cerebrospinal fluid after spinal cord injury.Normal human monocytes exposed to glioma cells acquire myeloid-derived suppressor cell-like properties.Laquinimod reduces neuroaxonal injury through inhibiting microglial activation.Resistance to oncolytic myxoma virus therapy in nf1(-/-)/trp53(-/-) syngeneic mouse glioma models is independent of anti-viral type-I interferon.Predominance of Th2 polarization by vitamin D through a STAT6-dependent mechanism.Toll-like receptor 2-mediated alternative activation of microglia is protective after spinal cord injury.Prolactin in combination with interferon-β reduces disease severity in an animal model of multiple sclerosisExperimental demyelination and remyelination of murine spinal cord by focal injection of lysolecithin.Reduced inflammation accompanies diminished myelin damage and repair in the NG2 null mouse spinal cord.ADAM-9 is a novel mediator of tenascin-C-stimulated invasiveness of brain tumor-initiating cells.1,25-Dihydroxyvitamin D3 Protects against Immune-Mediated Killing of Neurons in Culture and in Experimental Autoimmune Encephalomyelitis.An inhibitor of chondroitin sulfate proteoglycan synthesis promotes central nervous system remyelination.A novel anti-EMMPRIN function-blocking antibody reduces T cell proliferation and neurotoxicity: relevance to multiple sclerosisCortical remyelination: a new target for repair therapies in multiple sclerosis.Reduction of microglial activity in a model of multiple sclerosis by dipyridamole.Promoting oligodendrogenesis and myelin repair using the multiple sclerosis medication glatiramer acetate.Revisiting Mobility Limitations of Seniors in Singapore, 1995 to 2011.The many faces of EMMPRIN - roles in neuroinflammation.Inflammatory and structural biomarkers in acute traumatic spinal cord injury.The good, the bad and the ugly. Macrophages/microglia with a focus on myelin repair.Prolactin in multiple sclerosis.Pathophysiology of the brain extracellular matrix: a new target for remyelination.Remyelination after spinal cord injury: is it a target for repair?Interactions between microglia and T cells in multiple sclerosis pathobiology.The promise of futility trials in neurological diseases.Unique spectral signatures of the nucleic acid dye acridine orange can distinguish cell death by apoptosis and necroptosis.Immunosenescence of microglia and macrophages: impact on the ageing central nervous system.
P50
Q22252381-12DFB64D-D6B3-499A-B088-2ED2E17AD9A1Q26744475-186B30E3-0D78-4A24-BE93-A8E504636681Q26824246-2F115EEB-2CB0-4555-B7FF-A23EA4045FEFQ26998829-EBAD7B73-9133-4391-9DDF-56E37FB8B831Q27307045-09F12C68-DEB9-46BA-BB3F-77E0C25B28D0Q28087040-55ED7176-CE06-491A-A6A2-C3EDF7B4FC22Q30395978-6D52AB9B-A619-4C9B-96AB-ADC7520A6AA0Q30636334-393A6E9C-E13D-4C19-92E4-03C012F655DBQ30699586-2556EDC2-A610-4FCD-BCC5-AE199D18C272Q30831649-0204F73F-A1E8-4C1F-B920-78C4A5D4CB80Q30835527-84D7033B-93C2-4DA6-8D04-FD6B1F98AC0EQ34003724-C8ACA8AA-5BEA-44AD-85BB-747EA3EC9A78Q34086999-FDB6761D-405E-41ED-8C10-22E66B6CFE45Q34102648-6DEBD8B8-19EF-4B12-96E8-99D4AD02F519Q34132823-0F014B72-8147-40C4-A46E-A370A16AB0BAQ34286754-503278C5-4196-4474-8D51-D13A646F2C55Q34770256-4386A528-6681-4F56-A056-CA09B9C51D05Q35054693-9829014C-8337-4FF7-A0DB-E9E7F905D1C1Q35076145-23DB84BB-80C2-4126-82B6-0C65237B5346Q35201218-6B27D9A5-31FD-4A02-8B44-9763B499A3EBQ35461070-DA12CA28-F81D-4C6E-A4AC-F7D8E55B4F10Q35588967-8E4D207B-0471-45C4-A6EA-401E2F168D52Q35815285-2B80CDDF-BBEF-4605-9320-35CF455FD205Q35872062-9B1DAE27-1158-4F5C-A4B6-2FE4A1F50C0BQ35999574-FB2F5667-8084-4B83-A7E1-ED98BAC5A782Q36175816-22CC4F73-407F-43F5-A5FE-3183022B7DCDQ36504051-B82570A7-5475-4394-A1A6-31C03713B500Q37048242-AD5FC7EC-9885-4685-8AA8-5BAFB9B95EFAQ37378494-1353623A-0AC2-4E89-AC23-67D17D50F2DDQ37429660-0D48C724-EDDD-4007-B160-84968B3C44A3Q37776881-EE251800-65E9-4AC1-82D8-CA6E71839868Q37822789-15A94385-2231-4376-A7F8-817C5BDCA8E1Q37881680-08C7599C-582B-47CB-AFF4-C942B0F20D17Q38039054-4F69BB44-D719-4270-9F77-CC65A0E68305Q38132334-E8B5FE47-D1F7-4FCF-AD12-CE3AF5261C29Q38192321-582609E7-297F-4D29-8018-0DA67EA5C4E6Q38236021-80D1B387-3779-4756-BCCB-F6D9B8654728Q38380170-E060893E-CFA7-4DFC-BE9E-54FDA3F88C79Q38713422-6029B245-C67B-4077-A492-B56D3780BE24Q38749164-17683BC2-F224-4C5E-9678-24DE0455DEAF
P50
description
Forscher
@de
chercheur
@fr
investigador
@es
researcher
@en
ricercatore
@it
研究者
@zh
name
V Wee Yong
@ast
V Wee Yong
@en
V Wee Yong
@es
V Wee Yong
@nl
type
label
V Wee Yong
@ast
V Wee Yong
@en
V Wee Yong
@es
V Wee Yong
@nl
prefLabel
V Wee Yong
@ast
V Wee Yong
@en
V Wee Yong
@es
V Wee Yong
@nl
P31
P496
0000-0002-2600-3563